Duration of intrapartum antibiotics for group B streptococcus on the diagnosis of clinical neonatal sepsis

Mark A Turrentine, Anthony J Greisinger, Kimberly S Brown, Oscar A Wehmanen, Melanie E Mouzoon, Mark A Turrentine, Anthony J Greisinger, Kimberly S Brown, Oscar A Wehmanen, Melanie E Mouzoon

Abstract

Background: Infants born to mothers who are colonized with group B streptococcus (GBS) but received <4 hours of intrapartum antibiotic prophylaxis (IAP) are at-risk for presenting later with sepsis. We assessed if <4 hours of maternal IAP for GBS are associated with an increased incidence of clinical neonatal sepsis.

Materials and methods: A retrospective cohort study of women-infant dyads undergoing IAP for GBS at ≥37-week gestation who presented in labor from January 1, 2003 through December 31, 2007 was performed. Infants diagnosed with clinical sepsis by the duration of maternal IAP received (< or ≥4-hours duration) were determined.

Results: More infants whose mothers received <4 hours of IAP were diagnosed with clinical sepsis, 13 of 1,149 (1.1%) versus 15 of 3,633 (0.4%), P = .03. Multivariate logistic regression analysis showed that treatment with ≥4 hours of IAP reduced the risk of infants being diagnosed with clinical sepsis by 65%, adjusted relative risk 0.35, CI 0.16-0.79, and P = .01.

Conclusion: The rate of neonatal clinical sepsis is increased in newborns of GBS colonized mothers who receive <4 hours compared to ≥4 hours of IAP.

Figures

Figure 1
Figure 1
Study population.

References

    1. Centers for Disease Control Prevention. Prevention of perinatal group B streptococcal disease: a public health perspective. Morbidity and Mortality Weekly Report. 1996;45(RR-7):1–24.
    1. Centers for Disease Control Prevention. Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. Morbidity and Mortality Weekly Report. 2002;51(RR-11):1–22.
    1. Centers for Disease Control Prevention. Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. Morbidity and Mortality Weekly Report. 2010;59(RR-10):1–22.
    1. Boyer KM, Gadzala CA, Kelly PD, Gotoff SP. Selective intrapartum chemoprophylaxis of neonatal group B streptococcal early-onset disease. III. Interruption of mother-to-infant transmission. Journal of Infectious Diseases. 1983;148(5):810–816.
    1. Pylipow M, Gaddis M, Kinney JS. Selective intrapartum prophylaxis for group B Streptococcus colonization: management and outcome of newborns. Pediatrics. 1994;93(4):631–635.
    1. Lin FYC, Brenner RA, Johnson YR, et al. The effectiveness of risk-based intrapartum chemoprophylaxis for the prevention of early-onset neonatal group B streptococcal disease. The American Journal of Obstetrics and Gynecology. 2001;184(6):1204–1210.
    1. de Cueto M, Sanchez MJ, Sampedro A, Miranda JA, Herruzo AJ, Rosa-Fraile M. Timing of intrapartum ampicillin and prevention of vertical transmission of group B Streptococcus . Obstetrics and Gynecology. 1998;91(1):112–114.
    1. Lijoi D, Capua ED, Ferrero S, et al. The efficacy of 2002 CDC guidelines in preventing perinatal group B Streptococcal vertical transmission: a prospective study. Archives of Gynecology and Obstetrics. 2007;275(5):373–379.
    1. Berardi A, Rossi C, Biasini A, et al. Efficacy of intrapartum chemoprophylaxis less than 4 hours duration. Journal of Maternal-Fetal and Neonatal Medicine. 2011;24(4):619–625.
    1. Illuzzi JL, Bracken MB. Duration of intrapartum prophylaxis for neonatal group B streptococcal disease: a systematic review. Obstetrics and Gynecology. 2006;108(5):1254–1265.
    1. International Classification of Diseases 9th revision, Clinical Modification. 6th edition. Salt Lake City, Utah, USA: St. Anthony Publishing (Ingenix); 2008.
    1. Ottolini MC, Lundgren K, Mirkinson LJ, Cason S, Ottolini MG. Utility of complete blood count and blood culture screening to diagnose neonatal sepsis in the asymptomatic at risk newborn. Pediatric Infectious Disease Journal. 2003;22(5):430–434.
    1. Bromberger P, Lawrence JM, Braun D, Saunders B, Contreras R, Petitti DB. The influence of intrapartum antibiotics on the clinical spectrum of early-onset group B streptococcal infection in term infants. Pediatrics. 2000;106(2 I):244–250.
    1. Escobar GJ, Li DK, Armstrong MA, et al. Neonatal sepsis workups in infants ≥2000 grams at birth: a population-based study. Pediatrics. 2000;106(2 I):256–263.
    1. Goins WP, Talbot TR, Schaffner W, et al. Adherence to perinatal group B streptococcal prevention guidelines. Obstetrics and Gynecology. 2010;115(6):1217–1224.
    1. Schrag SJ, Zell ER, Lynfield R, et al. A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates. The New England Journal of Medicine. 2002;347(4):233–239.
    1. de Cueto M, Sanchez MJ, Molto L, et al. Efficacy of a universal screening program for the prevention of neonatal group B streptococcal disease. The European Journal of Clinical Microbiology and Infectious Diseases. 1995;14(9):810–812.
    1. Bloom SL, Cox SM, Bawdon RE, Gilstrap LC. Ampicillin for neonatal group B streptococcal prophylaxis: how rapidly can bactericidal concentrations be achieved? The American Journal of Obstetrics and Gynecology. 1996;175(4 I):974–976.
    1. Colombo DF, Lew JL, Pedersen CA, Johnson JR, Fan-Havard P. Optimal timing of ampicillin administration to pregnant women for establishing bactericidal levels in the prophylaxis of group B Streptococcus . The American Journal of Obstetrics and Gynecology. 2006;194(2):466–470.
    1. Barber EL, Zhao G, Buhimschi IA, Illuzzi JL. Duration of intrapartum prophylaxis and concentration of penicillin G in fetal serum at delivery. Obstetrics and Gynecology. 2008;112(2):265–270.
    1. Grimes DA. False alarms and pseudo-epidemics. The limitations of observational epidemiology. Obstetrics and Gynecology. 2012;120(4):920–927.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa